Noscira Presents Results of Phase IIa Clinical Trial with Nypta(R) (Tideglusib) on Alzheimer's Disease at International Conference on Alzheimer's Disease (ICAD)
- Treatment with Nypta(R) (Tideglusib) (NP-12) was tolerated and produced positive effects on Alzheimer's patients in four of the five efficacy variables examined in the trial.
- In view of the promising results of this trial, Noscira is preparing the next Phase IIb trial on Alzheimer's patients in order to progress with the clinical development of this novel compound.
MADRID, July 15 /PRNewswire/ -- Noscira, the Grupo Zeltia (ZEL.MC) subsidiary specialized in researching and developing drugs for treating neurodegenerative diseases, presented the results of a Phase IIa clinical trial of Nypta(R) (Tideglusib) on Alzheimer's disease (AD) at the International Conference on Alzheimer's Disease (ICAD), held in Honolulu (Hawaii) from July 10-15, 2010.
Dr. Teodoro del Ser, Director of Clinical Development at Noscira, gave an oral session in the "Therapeutic Strategies" symposium in which he reported that treatment with Nypta(R) (Tideglusib) for 20 weeks was tolerated and had a positive impact on patients' cognitive performance. In order for these results to be statistically significant, they must be confirmed in a Phase IIb trial in which a larger group of patients will be treated for one year.
The Phase IIa trial, which was conducted at three centers in Germany based on advice from experts at the European Medicines Agency (EMA), is the first clinical trial of Nypta(R) (Tideglusib) on a group of Alzheimer's patients. The trial was designed with the primary goal of assessing the safety and tolerability of Nypta(R) (Tideglusib) on these patients.